Premium
Fluoroquinolones as a trigger for rupture of abdominal aortic aneurysm: A case‐crossover analysis
Author(s) -
Lawaetz Kristensen Katrine,
Hallas Jesper,
Sanddal Lindholt Jes
Publication year - 2021
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.13591
Subject(s) - medicine , confounding , abdominal aortic aneurysm , cardiology , aneurysm , aortic rupture , aortic aneurysm , surgery
Fluoroquinolones (FQ) are associated with an increased risk of tendinopathy, including rupture. Our study aimed to investigate whether FQ use triggered the rupture of aortic aneurysms using a self‐controlled design. We hypothesised that the use of FQ was associated with aortic rupture shortly after redeemed FQ prescriptions. Using nationwide data sources, we performed a case‐crossover study of cases with ruptured aortic aneurysms. From 1996 to 2016, 58 persons presented with rupture of an aortic aneurysm and a redeemed prescription for any FQ within 28 days. 67% were men, and the median age was 77 years. Some 82.9% presented with a ruptured abdominal aneurysm. In our conditional regression, the crude OR for having rupture with a recent FQ redemption was 1.36 (CI 1.00‐1.86). After adjusting for potential confounders, the OR was 1.35 (CI 0.98‐1.85). Changing the hazard period to FQ redemption within 60 and 90 days, the OR was 2.16 (CI 1.70‐2.76) and 2.21 (CI 1.78‐2.75), respectively. In conclusion, we demonstrated an association between FQ use within 60 and 90 days and a diagnosis of ruptured aortic aneurysm.